Yudie Yang*1, Xia Zhang†1, Yajie Gao*, Yan Dong*, Di Wang*, Yanping Huang*, Tianhao Qu*, Buqun Fan*, Qizheng Li*, Chunxia Zhang*, Xiaonan Cui*, Bin Zhang*
Oncology Research, Vol.29, No.1, pp. 63-74, 2021, DOI:10.3727/096504022X16462176651719
Abstract Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune
checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater
extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer
(NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, there has been no major breakthrough in current immunotherapy. Whether immunotherapy can bring new benefits after drug resistance is More >
Login
Register
